ALK and cholangiocarcinoma: Similar findings were observed in a phase-I study where ceritinib, in combination with gemcitabine and cisplatin, conferred prolonged clinical benefits to a subset of evaluable CCA patients (n = 3/5) without ALK mutations [63].